Article
Immunology
Ruixin Li, Jiongtao Zhou, Zhengyuan Liu, Xi Chen, Qiqiang Long, Yan Yang, Shengyun Lin, Jinsong Jia, Guangsheng He, JianYong Li
Summary: The addition of eltrombopag to intensive immunosuppressive therapy can restore hematopoiesis in patients with severe aplastic anemia. A retrospective study found that baseline reticulocyte percentage, absolute reticulocyte count, red cell distribution width-coefficient of variation, and absolute lymphocyte count are potential predictors of treatment response at 6 months.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pediatrics
Yufei Zhao, Wenrui Yang, Xin Zhao, Xiangrong Hu, Jing Hu, Xu Liu, Jianping Li, Lei Ye, Youzhen Xiong, Yang Yang, Baohang Zhang, Xiaoxia Li, Xiawan Yang, Yimeng Shi, Guangxin Peng, Yuan Li, Huihui Fan, Kang Zhou, Liping Jing, Li Zhang, Fengkui Zhang
Summary: Adding EPAG to standard IST as the first-line treatment for children with acquired SAA improved the rapidity of hematological response and the complete response rate but did not improve the overall response or event-free survival rates.
FRONTIERS IN PEDIATRICS
(2023)
Article
Oncology
Limin Liu, Meiqing Lei, Rong Fu, Bing Han, Xin Zhao, Rongrong Liu, Yanming Zhang, Wenjing Jiao, Miao Miao, Fengkui Zhang, Liansheng Zhang, Depei Wu
Summary: This study compared the efficacy and safety of matched related donor-hematopoietic stem cell transplantation (MRD-HSCT) with immunosuppressive therapy plus eltrombopag (IST + EPAG) for severe aplastic anemia (SAA) patients. The results showed that MRD-HSCT achieved faster transfusion independence and better outcomes, making it the preferred first-line treatment option for younger patients or those with vSAA.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Ruixin Li, Ningling Wang, Xingxing Chai, Linhai Yang, Kangkang Liu, Hailong He, Shengyun Lin, Yan Yang, Jinsong Jia, Donghua Zhang, Yuemin Gong, Jinning Shi, Guangsheng He, Jianyong Li
Summary: Eltrombopag can enhance the effectiveness of immunosuppressive therapy in severe aplastic anemia patients. This study investigates the benefits of continuous usage of Eltrombopag beyond 6 months in these patients. The findings show that continuous administration of Eltrombopag improves hematologic response and event-free survival in patients without achieving complete remission at 6 months.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Immunology
Pengpeng Pan, Congcong Chen, Jian Hong, Yue Gu
Summary: Acquired aplastic anemia (AA) is an autoimmune disease characterized by depleted hematopoietic stem and progenitor cells (HSPCs) and peripheral blood cells. Although immunosuppressive therapy (IST) is an effective treatment, its limitations necessitate further research into the pathogenesis of AA and identification of new drug targets to improve outcomes.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Hematology
Lauren T. Shinn, Lydia L. Benitez, Anthony J. Perissinotti, Justin H. Reid, Kaitlyn M. Buhlinger, Hendrik van Deventer, Dylan Barth, Charlotte B. Wagner, Kyle Zacholski, Ruchi Desai, Ashley Soule, Sarah E. Stump, Taylor M. Weis, Dale Bixby, Patrick Burke, Kristen Pettit, Bernard L. Marini
Summary: Eltrombopag may not have as significant of an effect in real-world settings compared to controlled trial settings, but it can offer patients deeper treatment responses, with similar rates of toxicity to immunosuppressive therapy alone.
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2023)
Article
Immunology
Lingyun Chen, Meili Ge, Jiali Huo, Xiang Ren, Yingqi Shao, Xingxin Li, Jinbo Huang, Min Wang, Neng Nie, Jing Zhang, Jin Peng, Yizhou Zheng
Summary: HLA genotyping has a crucial value in predicting the outcome of IST and long-term survival in patients with aplastic anemia, and it may assist in developing an individualized treatment strategy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Hematology
Anastasia Martynova, Victor Chiu, Melissa Mert, David Hermel, Ilene Ceil Weitz
Summary: Research suggests that tacrolimus may be a potential treatment option for aplastic anemia with a more favorable toxicity profile compared to CsA.
ANNALS OF HEMATOLOGY
(2021)
Article
Hematology
Yuanyuan Jin, Ruixin Li, Shengyun Lin, Jinsong Jia, Yan Yang, Donghua Zhang, Guangsheng He, Jiangyong Li
Summary: The addition of low-dose EPAG to IST in Chinese patients with SAA resulted in higher response rates and complete remission rates, without significant adverse events.
ANNALS OF HEMATOLOGY
(2022)
Article
Oncology
Harry Lesmana, Timothy Jacobs, Michelle Boals, Nathan Gray, Sara Lewis, Juan Ding, Guolian Kang, Melvanique Hale, Mitchell Weiss, Ulrike Reiss, Winfred Wang, Marcin Wlodarski
Summary: This study evaluated the efficacy and safety of standard immunosuppressive therapy and combination therapy with eltrombopag in pediatric severe aplastic anemia patients. The results showed a higher objective response rate in the treatment group with eltrombopag added, and no significant differences in infections between the two therapies.
PEDIATRIC BLOOD & CANCER
(2021)
Article
Hematology
Bhavisha A. Patel, Danielle M. Townsley, Phillip Scheinberg
Summary: Severe aplastic anemia, a disease characterized by pancytopenia and a hypocellular marrow, can be treated with immunosuppressive therapy (IST) or hematopoietic stem cell transplant. Adding eltrombopag (EPAG) to the IST regimen improves treatment response rates without increasing the risk of myeloid malignancies. However, relapse remains a challenge, and further optimization of treatment protocols is needed.
SEMINARS IN HEMATOLOGY
(2022)
Article
Medicine, Research & Experimental
Wei Yu, Qianqian Wang, Meili Ge, Xue Shi
Summary: This study evaluated the correlation between natural killer (NK) cells and response to immunosuppressive therapy (IST) in severe aplastic anemia (SAA) patients. The findings showed that the proportion and absolute number of NK cells were significantly lower in newly diagnosed SAA patients compared to controls, but increased in complete remission patients treated with IST. Additionally, the proportion of NK cells at diagnosis was found to be a promising predictor of response to IST.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Medicine, General & Internal
Efreen Montano-Figueroa, David Gomez-Almaguer
Summary: The COVID-19 pandemic has caused changes in medical practice, leading to increased infection risk for patients with hematologic diseases requiring immunosuppressive therapy. Severe aplastic anemia with absolute neutrophil count less than 200/mu l is a life-threatening condition that may require delaying potentially curative treatments like bone marrow transplant. Outpatient immunosuppression with oral medications could be a suitable alternative to minimize infection risk during hospitalization.
GACETA MEDICA DE MEXICO
(2021)
Article
Hematology
Jing Hu, Li Zhang, Xin Zhao, Xu Liu, Liping Jing, Kang Zhou, Yuan Li, Yang Li, Jianping Li, Lei Ye, Guangxin Peng, Huihui Fan, Wenrui Yang, Yang Yang, Youzhen Xiong, Lin Song, Fengkui Zhang
Summary: This study investigated the hematologic responses and long-term overall survival outcomes in severe aplastic anemia (SAA) patients who received rabbit antithymocyte globulin (rATG) and cyclosporine as first-line immunosuppressive therapy. The results showed that 3 mg/kg/day rATG is effective as first-line treatment for SAA.
ANNALS OF HEMATOLOGY
(2022)
Article
Immunology
Yuanfeng Zhang, Jiali Huo, Li Liu, Yuyan Shen, Juan Chen, Tingting Zhang, Xin Chen, Aiming Pang, Donglin Yang, Rongli Zhang, Qiaoling Ma, Weihua Zhai, Yi He, Jialin Wei, Erlie Jiang, Mingzhe Han, Yizhou Zheng, Sizhou Feng
Summary: This study retrospectively compared the efficacy of different treatment strategies in 387 patients with acquired aplastic anemia (AA). The results showed that haploidentical donor HSCT had higher rates of graft failure and acute chronic GvHD compared with matched sibling donor HSCT and immunosuppressive therapy. HSCT had better blood count recovery compared with IST. In patients aged ≤40 years, MSD-HSCT was superior to HID-HSCT, while HID-HSCT and IST had similar overall survival rates but better failure-free survival rates when followed up for more than 14.5 months.
FRONTIERS IN IMMUNOLOGY
(2022)